Literature DB >> 22718150

The natural history of tractional cystoid macular edema.

Sofia Charalampidou1, John Nolan, Stephen Beatty.   

Abstract

BACKGROUND: To describe clinical outcomes in a series of patients with tractional cystoid macular edema, a variant of vitreomacular traction syndrome.
METHODS: Twelve consecutive patients (15 eyes) with tractional cystoid macular edema of maximum diameter of ≤550 μm and presenting corrected-distance visual acuity of ≤0.3 (Snellen ≥20/40) were studied. Each patient underwent ophthalmic examination, including visual acuity testing in the logarithm of the minimal angle of resolution system, slit-lamp biomicroscopy, and optical coherence tomography. All patients were monitored at four-monthly intervals, unless a subjective change in symptoms prompted earlier follow-up.
RESULTS: The mean corrected-distance visual acuity (±standard deviation) at presentation was 0.17 (Snellen 20/30) (±0.17). The mean (±standard deviation) maximum diameter of vitreofoveolar adhesion was 267 (±139) μm. After a mean follow-up of 9.2 (±7.4) months, 8 eyes exhibited spontaneous and complete posterior vitreous detachment, with resolution of the tractional cystoid macular edema and restoration of normal foveal anatomy in 6 of these eyes and persistence of a single foveal cyst in 2 of these eyes. The final corrected-distance visual acuity (±standard deviation) in the 5 eyes that underwent spontaneous and complete posterior vitreous detachment improved from 0.20 (Snellen 20/32) (±0.13) to 0.16 (Snellen 6/8) (±0.12; P = 0.53).
CONCLUSION: Complete posterior vitreous detachment occurred spontaneously in 53% of eyes with tractional cystoid macular edema in this series.

Entities:  

Mesh:

Year:  2012        PMID: 22718150     DOI: 10.1097/IAE.0b013e3182561fe6

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  A novel spectral-domain optical coherence tomography model to estimate changes in vitreomacular traction syndrome.

Authors:  Marco Codenotti; Lorenzo Iuliano; Giovanni Fogliato; Giuseppe Querques; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-25       Impact factor: 3.117

2.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

Review 3.  A review of current management of vitreomacular traction and macular hole.

Authors:  Alfredo García-Layana; José García-Arumí; José M Ruiz-Moreno; Lluís Arias-Barquet; Francisco Cabrera-López; Marta S Figueroa
Journal:  J Ophthalmol       Date:  2015-03-03       Impact factor: 1.909

4.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).

Authors:  Peter Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-22       Impact factor: 3.117

Review 5.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17

6.  Prognostic factors of postoperative intraretinal cystoid spaces after primary pars plana vitrectomy for vitreomacular traction.

Authors:  Razek Georges Coussa; Fares Antaki; Fatma Zaguia; Natalia Vila; Michael Alton Kapusta
Journal:  J Curr Ophthalmol       Date:  2019-06-28

7.  Factors Associated with the Clinical Course of Vitreomacular Traction.

Authors:  Petros Petrou; Evangelia Chalkiadaki; Marie-Helene Errera; Sidath Liyanage; Louisa Wickham; Evangelia Papakonstantinou; Aristotelis Karamaounas; Menelaos Kanakis; Ilias Georgalas; Stylianos Kandarakis; David Charteris
Journal:  J Ophthalmol       Date:  2020-12-21       Impact factor: 1.909

8.  Intra- and post-operative risk of retinal breaks during vitrectomy for macular hole and vitreomacular traction.

Authors:  Neil K Jairath; Yannis M Paulus; Angela Yim; Yunshu Zhou; Bela J Parekh; Ruple Jairath; David C Musch; Julie M Rosenthal
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.